Biogen’s Gilmore O’Neill Joins Sarepta as Chief Medical Officer

Xconomy Boston — 

Gilmore O’Neill has been appointed chief medical officer of Sarepta Therapeutics. O’Neill comes to the Cambridge, MA, biotech company from Biogen (NASDAQ: BIIB), where he was most recently senior vice president for all of the company’s clinical development. Sarepta’s first drug, eteplirsen (Exondys 51) won FDA approval in 2016 as a treatment for Duchenne muscular dystrophy. The company’s drug pipeline includes preclinical and clinical-stage compounds for rare neuromuscular diseases.